Stay updated on Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page history shows a new revision entry v3.3.2 added and an older revision v3.2.0 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedThe government funding notice banner was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedThe new screenshot shows only cosmetic UI updates to the Record History page, with the version history and study status details remaining the same as in the old screenshot. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check71 days agoChange DetectedSignificant update: added current operating status notice, current date, expanded study listing header with 2025-09-11 details, and revision v3.2.0; removed old date 2024-12-17 and revision v3.1.0.SummaryDifference14%

- Check78 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.2%

- Check92 days agoChange DetectedCore content now shows Revision: v3.0.2 replacing v3.0.1. The Back to Top link was removed (minor UI change).SummaryDifference0.6%

Stay in the know with updates to Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus MK-4830 in Ovarian Cancer Clinical Trial page.